SCHEMBL17599301

SCHEMBL17599301

CC(=O)Nc1ccc(C)c(S(=O)(=O)Nc2ccc(-c3cccc(C(=O)O)c3)c3ccccc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
GAA P10253 2/20 0.48
G6PD P11413 1/20 0.48
CKS1B P61024 1/20 0.47
SKP2 Q13309 1/20 0.47
RAD52 P43351 1/20 0.46
IDH1 O75874 5/20 0.46
HTT P42858 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PFKFB3 Q16875 1/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NR1H4 Q96RI1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599404 0.85 KMT2A (0.48) KMT2AMEN1GAAG6PDRAD52
SCHEMBL17599328 0.85 NR1H4 (0.53) KMT2AMEN1GAAHTTCYP3A4
SCHEMBL17599371 0.79 KMT2A (0.51) KMT2AMEN1HTTALDH1A1NPSR1
SCHEMBL17599329 0.79 KMT2A (0.55) KMT2AMEN1ALDH1A1NR1H4MCL1
SCHEMBL17613345 0.78 NR1H4 (0.44) KMT2AMEN1CKS1BSKP2CYP3A4
SCHEMBL17599351 0.78 KMT2A (0.45) KMT2AMEN1MCL1
SCHEMBL17599403 0.78 WDR5 (0.49) KMT2AMEN1L3MBTL1MCL1
SCHEMBL17599376 0.78 FABP4 (0.56) KMT2AMEN1GAAG6PDRAD52
SCHEMBL17599348 0.78 NPC1 (0.45) KMT2AMEN1GAAHTTCYP3A4
SCHEMBL17599312 0.77 KEAP1 (0.61) KMT2AMEN1GAACKS1BSKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed